|
| ORIGINAL ARTICLE |
|
| Year : 2010 | Volume
: 1
| Issue : 2 | Page : 260-267 |
 |
|
Evaluation of antioxidant potential of pyrazolone derivatives
G Mariappan, BP Saha, NR Bhuyan, PR Bharti, Deepak Kumar
Department of Pharmaceutical Chemistry, Himalayan Pharmacy Institute, E. Sikkim, India
| Date of Submission | 17-Apr-2010 |
| Date of Decision | 03-Jun-2010 |
| Date of Acceptance | 10-Jun-2010 |
| Date of Web Publication | 2-Nov-2010 |
Correspondence Address:
G Mariappan
Department of Pharmaceutical Chemistry, Himalayan Pharmacy Institute, E. Sikkim
India
 Source of Support: None, Conflict of Interest: None  | Check |
PMID: 22247854 
 Abstract | | |
In this article the antioxidant property of pyrazolones derivatives (PYZ1 to PYZ10) are reported. It was assessed by estimation of Malonaldehyde (MDA) and 4-Hydroxyl-2noneal (4-HNE) as lipid peroxidation markers in myocardial ischemic reperfusion injury. The inhibition of lipid peroxidation was compared with the standard ascorbic acid. Among synthesized derivatives PYZ2, PYZ3, PYZ7, PYZ8, PYZ9, and PYZ10 were found to have potent antioxidant effect against MDA marker. In case of 4-HNE, PYZ4, PYZ5, PYZ6, PYZ7, PYZ8, PYZ9 and PYZ10 were found to have effective antioxidant activity and the rest of the compounds are moderately active. Comparatively PYZ7, PYZ8, PYZ9 and PYZ10 are having effective role to control both MDA and 4-HNE generation. All the experimental data were statistically significant at p< 0.05 level. Interestingly, beyond its NSAID property, this study explores the protective role of pyrazolone derivatives in ischemic heart injury. Keywords: Lipid peroxidation, antioxidants, Malonaldehyde, 4-Hydroxyl-2-nonenal, pyrazolone
How to cite this article:
Mariappan G, Saha B P, Bhuyan N R, Bharti P R, Kumar D. Evaluation of antioxidant potential of pyrazolone derivatives. J Adv Pharm Technol Res 2010;1:260-7 |
How to cite this URL:
Mariappan G, Saha B P, Bhuyan N R, Bharti P R, Kumar D. Evaluation of antioxidant potential of pyrazolone derivatives. J Adv Pharm Technol Res [serial online] 2010 [cited 2021 Mar 6];1:260-7. Available from: https://www.japtr.org/text.asp?2010/1/2/260/72275 |
| Introduction | |  |
Pyrazolone derivatives have been used in patients with acute brain infarction since April 2001 in Japan [1]. These derivatives have been shown to be effective against brain edema after ischemia and reperfusion injury in animal models [2] and in stroke patients [3]. Moreover, it has been shown that these molecules have preventive effects on myocardial injury following ischemia and reperfusion in the rat heart [4] and in patients with acute myocardial infarction [5]. Several lines of evidence have demonstrated that oxidative stress plays an important role in the pathogenesis and development of cardiovascular diseases, including hypertension, hypercholesterolemia, diabetes mellitus, atherosclerosis, and myocardial infarction, angina pectoris, and heart failure [6]. Lipid peroxidation is found to cause formation of atherosclerotic plaques, neurological disorders, cancer, diabetes mellitus, myocardial infarction [7] and ageing. Lipid peroxidation is associated with ischaemia-reperfusion injury and hyperoxic lung injury. The peroxides derived from lipid peroxidation such as MDA (TBARS) and 4-HNE have been strongly associated with myocardial ischemic reperfusion injury [8],[9] . It is expected that pyrazolone derivatives have beneficial effects on coronary artery and myocardial cells after ischemic and post ischemic myocardial injury in patients with ischemic heart diseases, including acute myocardial infarction and angina pectoris. Some animal studies using acute myocardial ischemic-reperfusion models have suggested the protective effects of pyrazolone derivatives on myocardial damage. By taking this research finding as evidence, the present study is focused to explore the antioxidant potential of pyrazolone derivatives.
| Materials and Methods | | |
Pyrazolone derivatives were synthesized in our laboratory by reported procedure [10] , and used as test drugs in the experiments at 100 mg/ kg body weight. The physical data of the synthesized compounds have been given in [Table 1]. Thiobarbituric acid (TBA) was obtained from Loba Chemie, India. 2, 4-dinitrophenyl hydrazine (DNPH) and 1, 1, 3, 3-tetramethoxy propane (TMP) were obtained from Sigma Chemicals, USA. Ferrous sulphate, trichloroacetic acid (TCA), hydrogen peroxide, ascorbic acid, potassium dihydrogen phosphate, potassium hydroxide, hexane, methanol and HCl were of analytical grade and obtained from Ranbaxy Fine Chemicals. 4-HNE (4- Hydroxy- 2- Noneal) was obtained from Ranbaxy Ltd. As a gift sample. All other chemicals and reagents used were of analytical grade.
Experimental animals
Toxicological studies of the pyrazolone derivatives (as suspension in 0.5% w/v carboxy methylcellulose) were carried out by standard method in oral dose of 100 to 1500 mg/ kg body weight in albino mice. The LD 50 of the test compounds was found at 1000 mg/kg.b.w. The one tenth of the LD 50 (100mg/ kg) was considered to be the dose of test compounds. Male albino rats, weighing between 150-200gm were included in the study. Rats were housed in the departmental animal house at an ambient temperature of 25C, under a 12 h dark -12 h light, cycle, for the whole period of the study. Experiments were carried out according to the guidelines of the animal ethics committee of the institute. Animals were fasted overnight and were divided in to twelve group's i.e. control, standard and different test groups each consisting of three animals. Rats in the control group received the vehicle solution without drugs, rats in the standard group received the standard ascorbic acid (100mg/ kg p. o) and the pyrazolone derivatives were administered orally to the test group of rats.
In vitro myocardial ischemicreperfusion injury [11]
After 48 h the rats were anaesthetized with ether, the chest opened and the heart along with one cm of ascending aorta attached was quickly removed and dipped in ice-cold saline. The hearts were then mounted on Langendorff's apparatus and perfused with Krebs's Hensleit (K-H) buffer at a constant pressure of 60-70mm Hg at 3TC, and aerated with a mixture of O 2 (95%) and CO 2 (5%). Following an initial period of 5 min of stabilization, the flow was stopped for 9 min (ischemia) followed by perfusion with K-H buffer for 12 minutes (reperfusion). Then the heart was removed from the apparatus and subjected for the biochemical estimation.
In vitro antioxidant activity of pyrazolone derivatives Estimation of TBARS [12]
TBARS activity in the myocardium was determined by a modified version of the method described by Okhawa et.al. 1979. Hearts were homogenized in 10% trichloroacetic acid at 4C. 0.2 ml homogenate was pippeted in to a test tube followed by the addition of 0.2 ml of 8.1% sodiumdodecyl sulphate (SDS), 1.5 ml of 20% acetic acid (pH 3.5) and 1.5 ml of 0.8% TBA. All tubes were boiled for 60min at 90C and then cooled on ice. 1.0 ml double distilled water and Sml of n-Butanol: pyridine (15:1v/v) mixture was added to the tubes and centrifuged at 4000 rpm for 10 minute. The absorbance of developed colour in organic layer was measured at 532nm. TBARS activity was determined, from the standard curve of TBA adduct formation when various concentration of commercially available 1, 1, 3, 3-tetramethoxypropane was subjected to the above procedure [Figure 1] and [Figure 2]. The concentration of MDA was expressed in nM. | Figure 2: Antioxidant activity of Pyrazolone derivatives on MDA suppression model C-Control, Std-Ascorbic acid
Click here to view |
Estimation of 4-HNE [13]
The heart homogenate was prepared as the procedure mentioned above. 2ml of filtrate was taken in a 13 x 100mm glass tube with cap. 1ml of DNPH was added to all the tubes containing heart homogenate, mixed thoroughly and set aside for lh to react with 4-HNE. Then the formed adduct of 4-HNE and DNPH was extracted by hexane, which was evaporated under argon at 40C. After cooling, 2 ml of methanol was added to all the samples and the absorbance was measured at 350 nm in the spectrophotometer. The quantity of 4HNE was calculated by linear regression analysis. The cone. Of 4-HNE present in myocardial tissues was expressed in nM [Figure 3] and [Figure 4]. | Figure 4: Antioxidant activity of Pyrazolone derivatives on 4-HNE suppression model C-Control, Std-Ascorbic acid
Click here to view |
| Results and Discussion | | |
The experimental study was based on the estimation of MDA and 4-HNE and their suppression by the pyrazolone derivatives are presented in [Table 2]. From the experimental results, it has been proved that the pyrazolone derivatives have significant antioxidant activity. The quantification of MDA and 4-HNE can be directly correlated with the lipid peroxidation inhibition capacity of the pyrazolone derivatives. The toxic radicals' quantification is also an indicator to monitor the overall progress of lipid peroxidation which is associated with myocardial ischemic reperfusion injury. The antioxidant activity of pyrazolone derivative was compared with standard antioxidant (ascorbic acid). The results were analyzed statistically and found significant at P<0.05 level. | Table 2: In vitro antioxidant activity of pyrazolone derivatives by MDA and 4-HNE model
Click here to view |
| Acknowledgement | | |
The authors are thankful to the Director Dr. H. P. Chhetri, Himalayan Pharmacy Institute, Majhitar, East Sikkim who provided the facilities to carry out the research work. The authors are also grateful to Dr. L. Sutharson H.O.D. of Pharmacology, HPI, Sikkim for his valuable suggestions.
| References | | |
| 1. | Otomo E. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebocontrolled, double blind study at multicenter. Cerebrovasc Dis. 2003; 15:222-229. 
|
| 2. | Nishi H., Watanabe T., Sakurai H., Yuki S., Ishibashi A. Effect of MCI186 on brain edema in rats. Stroke. 1989; 20:1236-1240.
|
| 3. | Toyoda K., Fujii K., Kamouchi M. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J. Neurol Sci. 2004; 221:11-17.
|
| 4. | Yanagisawa A., Miyagawa M., Ishikawa K., Murota S. Cardio protective effect of MCI-186 (3methyl- l-phenyl-2-pyrazolin-5-one) during acute ischemic-reperfusion injury in rats. Int. J. Angiology. 1994; 3:12-15.
|
| 5. | Tsujita K., Shimomura H., Kawano H. Effects of edaravone on reperfusion injury in patients with myocardial infarction. Am. J. Cardiol. 2004; 94:481-484.
|
| 6. | Chien KR. Stress pathways and heart failure. Cell. 1999; 98:555-558.
|
| 7. | Uchida K., Stadtman E.R. Quantitation of 4-hydroxynonenal protein adducts. Methods in enzymology.1994; 233:371- 379.
|
| 8. | Blasig I.E., Grune T., Schonheit K., Rohde E . , Jakstadt M., Haseloff R.F. Siems W.G. 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Heart and Cir Physiol.1995; 269: 14-22.
|
| 9. | Ski Kami K., Bonda T., Wojtkowska I., Dobrzycki S., Kralisz P., Nowak K., Prpkopczuk P., Skrzydlewska E., Kozuch M., Musil W.J. Oxidative stress and an tioxidative defense parameters early after reperfusion therapy for acute myocardial infarction. Acute Cardiac Care. 2008; 10:121-126.
|
| 10. | Haldar A. M. Pharm Thesis submitted to North Bengal University, West Bengal, India, 2009.
|
| 11. | Borchgrevink P.C., Schie R., Bergan A.S., Bakoy O.E., Jynge P. Magnesium and reperfusion of ischemic rat heart as assessed by 31P NMR. Am. J. Physiol. 1989; 256:11195-11204.
|
| 12. | Ohkawa H., Oshishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid. Anal. Biochem. 1979; 95: 351-358.
|
| 13. | Esterbauer H., Schaur R.J., Zollner H. Chemistry and biology of 4hydroxynonenal, malonylaldehyde and related aldehydes. Free Radic Biol. Med. 1991; 11:81-128.
|
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2]
| This article has been cited by | | 1 |
Enantioselective synthesis of unsymmetrical diaryl-substituted spirocyclohexanonepyrazolones through a cascade [4+2] double Michael addition |
|
| Zhang JX, Li NK, Liu ZM, Huang XF, Geng ZC, Wang XW. | | Advanced Synthesis and Catalysis. 2013; 355(4): 797-808 | | [Pubmed] | | | 2 |
Pd-catalyzed asymmetric allylic alkylation of pyrazol-5-ones with allylic alcohols: The role of the chiral phosphoric acid in C-O bond cleavage and stereocontrol |
|
| Tao, Z.-L. and Zhang, W.-Q. and Chen, D.-F. and Adele, A. and Gong, L.-Z. | | Journal of the American Chemical Society. 2013; 135(25): 9255-9258 | | [Pubmed] | | | 3 |
Highly enantioselective synthesis of spiro[cyclohexanone-oxindoles] and spiro[cyclohexanone-pyrazolones] by asymmetric cascade [5+1] double Michael reactions |
|
| Wu, B. and Chen, J. and Li, M.-Q. and Zhang, J.-X. and Xu, X.-P. and Ji, S.-J. and Wang, X.-W. | | European Journal of Organic Chemistry. 2012; (7): 1318-1327 | | [Pubmed] | | | 4 |
Cardioprotective potential of simvastatin in the hyperhomocysteinemic rat heart |
|
| Rohilla A, Khanam R, Khan MU. | | Journal of Advanced Pharmaceutical Technology and Research. 2012; 3(3): 193-198 | | [Pubmed] | | | 5 |
DABCO-mediated one-pot sequential transformation: Convenient access to fluorinated 1H-pyrazol-5(4H)-ones |
|
| Wu JW, Li F, Zheng Y, Nie J. | | Tetrahedron Letters. 2012; 53(36): 4828-4831 | | [Pubmed] | | | 6 |
Highly diastereo- and enantioselective organocatalytic one-pot sequential 1,4-addition/dearomative-fluorination transformation |
|
| Li F, Sun L, Teng Y, Yu P, Zhao JC, Ma JA. | | Chemistry - A European Journal. 2012; 18(45): 14255-14260 | | [Pubmed] | | | 7 |
Core scaffold-inspired stereoselective synthesis of spiropyrazolones via an organocatalytic Michael/cyclization sequence |
|
| Liu, L., Zhong, Y., Zhang, P., Jiang, X., Wang, R. | | Journal of Organic Chemistry. 2012; 77(22): 10228-10234 | | [Pubmed] | | | 8 |
Synthesis, characterization, in-vitro anti-oxidant And cytotoxic activity of n-mannich bases of 5-Amino-4-[2-(6-bromo-1, 3-benzo thiazol-2-yl) Hydrazinylidene]-2, 4-dihydro-3h-pyrazol-3-one |
|
| KK. Sivakumar, A. Rajasekharan,S. Buggareddy | | INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY. 2012; 2(2) | | [Pubmed] | | | 9 |
Extraction of saponin from Camellia oleifera cake and evaluation of its antioxidant activity |
|
| Hu JL, Nie SP, Huang DF, Li C, Xie MY. | | International Journal of Food Science & Technology. 2012; 2(47): 1676-1687 | | [Pubmed] | | | 10 |
Highly enantioselective Michael addition of pyrazolin-5-ones catalyzed by chiral metal/N,N′-dioxide complexes: Metal-directed switch in enantioselectivity |
|
| Wang, Z. and Yang, Z. and Chen, D. and Liu, X. and Lin, L. and Feng, X. | | Angewandte Chemie - International Edition. 2011; 50(21): 4928-4932 | | [Pubmed] | | | 11 |
Asymmetric α-amination of 4-substituted pyrazolones catalyzed by a chiral Gd(OTf)3/ N,N′-dioxide complex: Highly enantioselective synthesis of 4-amino-5-pyrazolone derivatives |
|
| Yang, Z. and Wang, Z. and Bai, S. and Liu, X. and Lin, L. and Feng, X. | | Organic Letters. 2011; 13(4): 596-599 | | [Pubmed] | | | 12 |
The diverse pharmacological importance of Pyrazolone Derivatives : A Review |
|
| Mariappan G, Saha BP, Sutharson L, et al | | Journal of Pharmacy Research. 2010; 3(12): 2856-2859 | | [Pubmed] | |
|
 |
|
|
|
